Furthermore, overcoming the therapeutic limitation posed by TSA heterogeneity and tumour escape via loss of cell surface antigen has been considered by targeting multiple MAAs (e.g., CSPG4 alongside tyrosinase-related protein 1). Here, CSPG4 is linked to neoplasm.